Form 4: OmniAb CFO Gustafson Reports RSU Vesting, New Grants

OmniAb's Executive VP, Finance and CFO, Kurt A. Gustafson, reported the vesting of restricted stock units, a tax-related share sale, and new grants of restricted stock units and stock options.

Summary

• Kurt A. Gustafson, Executive VP, Finance and CFO of OmniAb, Inc. (OABI), reported transactions occurring on February 18, 2026.
• 18,750 shares of common stock vested from a Restricted Stock Unit (RSU) grant, which vests in three substantially equal annual installments starting on this date.
• 9,301 shares of common stock were sold at a weighted average price of $1.71 per share (ranging from $1.68 to $1.73) to cover tax withholding obligations related to the RSU vesting. This was a mandated "sell-to-cover" transaction.
• Gustafson acquired 60,000 new Restricted Stock Units (RSUs), which will vest in three substantially equal annual installments beginning on February 18, 2027.
• Gustafson also acquired 600,000 new stock options with an exercise price of $1.71, expiring on February 18, 2036. These options vest as to 12.5% six months after the grant date, and then in 42 substantially equal monthly installments thereafter.
• Following these transactions, Gustafson directly beneficially owns 268,851 shares of common stock, 124,584 Restricted Stock Units, and 600,000 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive due to the new equity grants (RSUs and stock options) to a key executive, which can align management incentives with long-term company performance, despite the routine sell-to-cover transaction.

Positives

• Grant of 60,000 new Restricted Stock Units (RSUs) to the CFO, aligning executive incentives with shareholder value.
• Grant of 600,000 new stock options to the CFO, providing long-term incentive and potential future equity ownership.

Negatives

• Sale of 9,301 shares of common stock to cover tax withholding obligations, reducing direct share ownership.

Future Outlook

The filing details future vesting schedules for executive compensation, including 60,000 Restricted Stock Units vesting in three annual installments starting February 18, 2027, and 600,000 stock options vesting over approximately 3.5 years, beginning six months after the February 18, 2026 grant date.

Industry Context

StockSavvy.ai notes that executive compensation packages, often including equity grants like RSUs and stock options, are standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize key leadership. These grants typically align management's long-term interests with shareholder value creation.

Related Party Transactions

• The filing details transactions by Kurt A. Gustafson, an executive officer of OmniAb, Inc., involving the vesting of Restricted Stock Units, a tax-related sale of common stock, and the grant of new Restricted Stock Units and stock options. These are considered related party transactions as they involve an insider of the company.

Stakeholder Impact

• Shareholders: The new equity grants could be seen as a positive for aligning executive incentives with shareholder interests. The sell-to-cover transaction has a minimal dilutive effect.
• Management: Directly impacts the compensation and equity holdings of Kurt A. Gustafson.

Next Steps

• Future annual vesting installments for the 18,750 RSU grant beginning February 18, 2026.
• Future annual vesting installments for the 60,000 RSU grant beginning February 18, 2027.
• Future monthly vesting installments for the 600,000 stock option grant, starting six months after February 18, 2026.

Key Dates

Keywords

OmniAb, OABI, Form 4, insider transaction, executive compensation, Restricted Stock Units, RSU, stock options, Kurt A. Gustafson, sell-to-cover